World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
80
Citations
26905
World Ranking
17001
National Ranking
1545

Overview

Mark R. Middleton is affiliated with the University of Oxford in the United Kingdom. Their research spans a broad range of topics primarily within the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a particular focus on oncology and related subfields.

The main fields of study covered by their work include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Within these areas, their subfields of study comprise:

  • Oncology
  • Immunology
  • Molecular Biology
  • Genetics
  • Cancer Research

The research topics most frequently addressed include:

  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • Melanoma and MAPK Pathways
  • Cancer Genomics and Diagnostics
  • Virus-based gene therapy research
  • Cutaneous Melanoma Detection and Management

Mark R. Middleton has published extensively in several academic venues. The most frequent publication outlets are:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Regular and Young Investigator Award Abstracts
  • bioRxiv (Cold Spring Harbor Laboratory)
  • European Journal of Cancer

Their recent papers include:

  • "Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial" (2020, The Lancet Oncology)
  • "Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma" (2020, Nature Medicine)
  • "European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment" (2020, European Journal of Cancer)
  • "Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma" (2020, Clinical Cancer Research)
  • "European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention" (2020, European Journal of Cancer)

Frequent collaborators in research include:

  • Joseph J. Sacco
  • Benjamin P. Fairfax
  • Pippa Corrie
  • Nicholas Coupe
  • Anna Olsson-Brown

Best Publications

  • Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

    Keith T. Flaherty;Caroline Robert;Peter Hersey;Paul Nathan

  • Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

    Jeffrey Weber;Mario Mandala;Michele Del Vecchio;Helen J. Gogas

  • Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma

    Mark R Middleton;J J Grob;N Aaronson;G Fierlbeck

  • The safety and feasibility of extracorporeal high-intensity focused ultrasound (HIFU) for the treatment of liver and kidney tumours in a Western population

    R O Illing;J E Kennedy;F Wu;G R ter Haar

  • Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.

    John P. Neoptolemos;Malcolm J. Moore;Trevor F. Cox;Juan W. Valle

  • High-intensity focused ultrasound for the treatment of liver tumours.

    J.E. Kennedy;F. Wu;G.R. ter Haar;F.V. Gleeson

  • Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline

    Alexander Stratigos;Claus Garbe;Celeste Lebbe;Josep Malvehy

  • Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors

    Ruth Plummer;Christopher Jones;Mark Middleton;Richard Wilson

  • Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2012

    Claus Garbe;Ketty Peris;Axel Hauschild;Philippe Saiag

  • Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.

    Paolo A. Ascierto;Michele Del Vecchio;Mario Mandalá;Helen Gogas

  • Optimal Duration and Timing of Adjuvant Chemotherapy After Definitive Surgery for Ductal Adenocarcinoma of the Pancreas: Ongoing Lessons From the ESPAC-3 Study

    Juan W. Valle;Daniel Palmer;Richard Jackson;Trevor Cox

  • Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma

    Robert H. I. Andtbacka;Frances Collichio;Kevin J. Harrington;Mark R. Middleton

  • Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline

    Celeste Lebbe;Jürgen C Becker;Jean-Jacques Grob;Josep Malvehy

  • Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A.

    Carmela De Santo;Ramon Arscott;Sarah Booth;Ioannis Karydis

  • Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial

    William Greenhalf;Paula Ghaneh;John P. Neoptolemos;Daniel H. Palmer

  • Adjuvant Interferon in High-Risk Melanoma: The AIM HIGH Study—United Kingdom Coordinating Committee on Cancer Research Randomized Study of Adjuvant Low-Dose Extended-Duration Interferon Alfa-2a in High-Risk Resected Malignant Melanoma

    Barry W Hancock;Keith Wheatley;S Harris;Natalie J Ives

  • The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer

    Srinivasan Madhusudan;Mark R. Middleton

  • European interdisciplinary guideline on invasive squamous cell carcinoma of the skin : Part 2. Treatment

    Alexander J Stratigos;Claus Garbe;Clio Dessinioti;Celeste Lebbe

  • Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma.

    Benjamin P. Fairfax;Chelsea A. Taylor;Robert A. Watson;Isar Nassiri

  • Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma

    John M. Kirkwood;Lars Bastholt;Caroline Robert;Jeffrey A Sosman

Frequent Co-Authors

Paul Lorigan
Paul Lorigan University of Manchester
Geoffrey P. Margison
Geoffrey P. Margison University of Manchester
Michele Maio
Michele Maio University of Siena
Michael L. Dustin
Michael L. Dustin University of Oxford
Helen Gogas
Helen Gogas National and Kapodistrian University of Athens
James Larkin
James Larkin Royal Marsden NHS Foundation Trust
adrian l harris
adrian l harris University of Oxford
Omid Hamid
Omid Hamid Cedars-Sinai Medical Center
Dirk Schadendorf
Dirk Schadendorf University of Duisburg-Essen
David J. Kerr
David J. Kerr University of Oxford

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative and supplemental pathways to traditional medical education can open new doors in healthcare. Many aspiring professionals seek flexible options, such as the dnp program without clinical hours—ideal for those balancing work or familial commitments while aiming to advance to doctoral-level nursing leadership.

For students wanting to enter the workforce rapidly, choosing a 6 month lpn program provides a fast track to practical nursing positions, allowing graduates to gain hands-on experience sooner.

Those interested in mental health and advanced practice nursing may consider psych np online programs. These specialized Master’s degrees prepare nurses for high-demand roles in psychiatric and mental health services, often with accelerated or flexible schedules.

Additionally, if your passion lies in the administrative or management side of healthcare, a focus on the cheapest online health science degree can provide a cost-effective route to impactful careers in healthcare leadership and policy.

Best Scientists Citing Mark R. Middleton

Trending Scientists

Recently Published Articles